How GLP-1s work
GLP-1 medications that influence insulin secretion and glucose metabolism, and can also suppress appetite.
Reduce blood sugar
GLP-1s reduce blood sugar by increasing insulin, reducing glucagon
Promote fullness
GLP-1s promote feelings of fullness by slowing gastric emptying
Reduce cravings
GLP-1s reduce hunger cravings by acting on brain appetite centers
Measuring the market
Obesity Rates
+3X
U.S. adult obesity rates have tripled since 19602
GLP-1 Use
+700%
From 2019–2023, a +700% increase in GLP-1 prescriptions for non-diabetic patients3
Projected Growth
~15M
~15M obese patients projected to be on GLP-1 medications by 20304
Lifestyle Change
55%
55% of current users, 54% "GLP-1 interested" wish medical science could help them make lifestyle changes5
Targeted Nutrition
Solutions for during & after GLP-1 treatment
Metabolic changes with GLP-1 use can contribute to nutritional gaps, adverse symptoms and discomfort. Cargill offers solutions to support these unique dietary needs at every stage of the consumer journey.
Promote gastrointestinal health
Slowdown in gastric motility and reduced thirst can prompt GI complaints, which may lead to premature treatment cessation.6
Maintain muscle mass
Weight loss can often lead to loss of lean body mass, leaving users concerned about muscle volume, health and function.
Deliver hydration
GLP-1 medications can suppress feelings of thirst and result in reduced fluid intake.7,8
Salts / Electrolytes
- Potassium chloride
- Potassium citrate
- Sodium citrate
- Sea salt
- Pink Himalayan salt
Promote satiety
GLP-1 users report reduced food cravings. Post-treatment, when food cues return, it's important to manage calorie consumption and positive nutrition.
Maintain weight loss
As the biological drive to lose weight subsides, positive nutrition can support a stable, maintainable body weight.
Sweeteners
- EverSweet® stevia sweetener
- EverSweet® stevia sweetener + ClearFlo® natural flavor
- ViaTech® stevia sweetener
- Zerose® erythritol
- Xtend® sucromalt
Formulating for function and enjoyment
Take the next step
Talk to an expert
Leverage Cargill ingredients and expertise to enable success in the developing market for weight management nutrition.
Additional resources from Cargill
Nutritional beverage powders up their game
Powdered beverage mixes have elevated their performance and expanded into the mainstream. But these higher expectations bring formulation challenges. Cargill technical experts unpack solutions for delivering on complex goals.
Identifying Consumer Priorities in Nutritional Beverages
Functional beverages not only quench thirst; they also support consumers’ health, nutrition and active lifestyle goals. Learn how to craft products that hit consumer hot buttons.
GLP-1 nutritional solutions
From plant-based proteins to next-generation sweeteners, dietary fibers to probiotics, Cargill offers a full portfolio of ingredients to support innovation in the weight wellness space – together with formulation expertise to make them irresistible.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. EverSweet® is a product of Avansya, a joint venture of Cargill and dsm-firmenich. PURIS® Pea Protein is a trademark of PURIS Foods, a Cargill strategic partner.
Some Cargill products are only approved for use in certain geographies, end uses, and/or at certain usage levels. It is the customer's responsibility to determine, for a particular geography, that (i) the Cargill product, its use and usage levels, (ii) the customer's product and its use, and (iii) any claims made about the customer's product, all comply with applicable laws and regulations.
SOURCES:
- CDC.gov. "Adult Obesity Facts." May 2024.
- WorldObesity.org. Global Obesity Observatory.
- The BMJ. "GLP-1 Agonists: US Sees 700% Increase Over Four Years in Number of Patients Without Diabetes Starting Treatment." 386:q1645. July 23, 2024.
- J.P. Morgan. "The Increase in Appetite for Obesity Drugs." November 29, 2023.
- Kantar GLP-1 Study, Kantar U.S. MONITOR 2024.
- Paccou, et al. The Lancet; Diabetes & Endocrinology. 2024. Neeland, et al. Diabetes, Obesity and Metabolism. 2024;26(Suppl. 4):16–27.
- Kommu & Berg. Obesity Reviews. 2024;25:e13792.
- Almandoz, et al. Obesity. 2024.